Cardiac Cirrhosis and Congestive Hepatopathy

Updated: Jan 03, 2020
Author: Mansoor Arif, MD; Chief Editor: Gyanendra K Sharma, MD, FACC, FASE 



Cardiac cirrhosis (congestive hepatopathy) includes a spectrum of hepatic derangements that occur in the setting of right-sided heart failure. Clinically, the signs and symptoms of congestive heart failure (CHF) dominate the disorder. Unlike cirrhosis caused by chronic alcohol use or viral hepatitis, the effect of cardiac cirrhosis on overall prognosis has not been clearly established. As a result, treatment is aimed at managing the underlying heart failure.[1, 2]

Distinguishing cardiac cirrhosis from ischemic hepatitis is important. The latter condition may involve massive hepatocellular necrosis caused by sudden cardiogenic shock or other hemodynamic collapse. Typically, sudden and dramatic serum hepatic transaminase elevations lead to its discovery. Although cardiac cirrhosis and ischemic hepatitis arise from distinct underlying cardiac lesions (right-sided heart failure in the former and left-sided failure in the latter), in clinical practice they may present together.

Despite its name, cardiac cirrhosis (which usually implies congestive hepatopathy that results in liver fibrosis) rarely satisfies strict pathologic criteria for cirrhosis. The terms congestive hepatopathy and chronic passive liver congestion are more accurate, but the name cardiac cirrhosis has become convention. For the remainder of this chapter, the term cardiac cirrhosis will be used to mean congestive hepatopathy with or without liver fibrosis.

Cardiac cirrhosis and congestive hepatopathy. Cong Cardiac cirrhosis and congestive hepatopathy. Congestive hepatopathy with large renal vein.
Cardiac cirrhosis and congestive hepatopathy. Cong Cardiac cirrhosis and congestive hepatopathy. Congestive hepatopathy with large inferior vena cava.


Decompensated right ventricular or biventricular heart failure causes transmission of elevated right atrial pressure to the liver via the inferior vena cava and hepatic veins. At a cellular level, venous congestion impedes efficient drainage of sinusoidal blood flow into terminal hepatic venules. Sinusoidal stasis results in accumulation of deoxygenated blood, parenchymal atrophy, necrosis, collagen deposition, and, ultimately, fibrosis.

A separate theory proposes that cardiac cirrhosis is not simply a response to chronically increased pressure and sinusoidal stasis. Because intrahepatic vascular lesions are confined to areas of the liver with higher fibrotic burden, cardiac cirrhosis may require a higher grade of vascular obstruction, such as intrahepatic thrombosis, for its development. Thus, thrombosis of sinusoids and terminal hepatic venules propagates to medium-sized hepatic veins and to portal vein branches, resulting in parenchymal extinction and fibrosis.

Upon microscopic examination, sinusoidal engorgement, hepatocyte atrophy, and hemorrhagic necrosis is present in zone 3 of the hepatic acinus.[3]  Also, there can be fatty change, cholestasis, and bile thrombi in the canaliculi.


Causes of cardiac cirrhosis mirror the many etiologies of right-sided congestive heart failure (CHF), including congenital heart disease. Although inferior vena caval thrombosis and Budd-Chiari syndrome exhibit similar pathophysiology, they are categorized separately and are not included as causes of cardiac cirrhosis.

The most frequent causes of cardiac cirrhosis are the following:

  • Ischemic heart disease (31%)

  • Cardiomyopathy (23%)

  • Valvular heart disease (23%)

  • Primary lung disease (15%)

  • Pericardial disease (8%)

A study by Yoo et al suggested that the Fontan procedure is a significant risk factor for cardiac cirrhosis. The study included 46 patients with Fontan circulation, as well as 26 patients with right-sided heart failure and hepatic congestion. The Fontan patients were found, via transient elastography, to have a significantly higher liver-stiffness value than did the patients with right-sided heart failure. Moreover, a significant association was seen between liver stiffness in the Fontan patients and total bilirubin and albumin levels, white blood cell counts, and aspartate aminotransferase-to-platelet ratio indexes. The investigators found the age at which the Fontan procedure was completed and the total bilirubin level to be independent risk factors for hepatopathy.[4]


United States data

Cardiac cirrhosis rarely occurs in the United States. Its true prevalence is difficult to estimate because the disease typically remains subclinical and undiagnosed. The incidence of cardiac cirrhosis at autopsy has decreased significantly over the past several decades. This may be due to lower rates of uncorrected rheumatic heart disease and constrictive pericardial disease.

Sex- and age-related demographic

Comparative sex data for cardiac cirrhosis do not exist. However, because CHF is more common in men than women in the United States, the same is likely for cardiac cirrhosis.[5]

No published data regard age and cardiac cirrhosis exist. However, the prevalence of cardiac cirrhosis in the United States, like that of congestive heart failure almost certainly increases with age.


Prognosis depends on the severity of the underlying heart disease and the degree of heart failure. 

It has been proposed that use of the Fibrosis-4 index (Fib-4 index) (age [years] × aspartate aminotransferase [IU/L]/platelet count [109/L] × square root of alanine aminotransferase [IU/L]) can calculate a score to predict all-cause mortality in patients with liver cirrhosis.[6] A higher score on this index can predict a higher all-case mortality.[6]

Early recognition and medical treatment of the underlying heart disease is paramount in providing the best possible outcome to affected patients. 


The effect of cardiac cirrhosis on mortality and morbidity rates is unknown. The severity of the patient's underlying cardiac disease, which is typically advanced and chronic, is the major determinant of overall outcome.




Symptoms of CHF almost always mask gastrointestinal symptoms. Symptoms typically progress insidiously but may present suddenly and dramatically in cases of constrictive pericarditis or acute right ventricular decompensation. Patients may present with asymptomatic liver enzyme abnormalities, jaundice, and right upper quadrant discomfort. Case reports of fulminant hepatic failure have also been reported.

In addition to CHF, a patient's past medical history is likely to include one or more of the following:

  • Coronary artery disease

  • Myocardial infarction

  • Hypertension

  • Dilated cardiomyopathy

  • Valvular heart disease

  • Chronic alcohol abuse

  • Chronic obstructive pulmonary disease (COPD)

  • Cor pulmonale

  • Pulmonary hypertension

  • Constrictive pericarditis

  • Rheumatic heart disease

Symptoms may be divided into those that accompany right ventricular heart failure and the additional findings of biventricular failure.

Symptoms associated with isolated right-sided heart failure are as follows:

  • Dependent edema and weight gain

  • Increased abdominal girth

  • Right upper quadrant abdominal pain

  • Nocturia

  • Progressive fatigue

  • Anorexia, nausea, and vomiting

Symptoms associated with biventricular heart failure are as follows:

  • Progressive dyspnea

  • Orthopnea

  • Paroxysmal nocturnal dyspnea

  • Wheezing and/or cough (ie, cardiac asthma)

  • Anxiety: Multifactorial causes include dyspnea, palpitations, and increased sympathetic tone.

Physical Examination

Signs of heart failure dominate the physical examination findings.


Edema typically occurs in the lower extremities and dependent regions, which may progress to anasarca in cases of advanced and untreated heart failure. Chronic edema may be associated with lower extremity pigmentation, induration, and cellulitis.

Jugular venous pressure

Jugular venous pressure is elevated. Further distention of neck veins may be elicited with application of pressure over the right upper quadrant for as long as 1 minute (ie, hepatojugular reflux).

Paradoxical rise in jugular venous pressure during inspiration (ie, Kussmaul sign) may indicate constrictive pericarditis, right ventricular heart failure, tricuspid stenosis, or cor pulmonale.

Right atrial pressure recordings reveal large a waves, indicating elevated right atrial pressure that may appear as presystolic liver pulsations.

Prominent v waves with rapid y descent indicate tricuspid regurgitation. Progression to a systolic, or c-v, wave occurs in severe tricuspid insufficiency and may appear as systolic liver pulsations.[7]


Rales on lung examination indicate biventricular CHF. Decreased basilar breath sounds from pleural effusion also are common.

Cardiac abnormalities

Cardiac examination may reveal abnormalities related to right ventricular failure, tricuspid regurgitation, or both.

Abnormal systolic sternal or left parasternal lift signifies both pulmonary and right ventricular hypertension.

Right ventricular third and fourth heart sounds commonly are appreciated at the lower left sternal border of the sternum or over the xiphoid. Right ventricular S 3 suggests right ventricular failure. Right ventricular S 4 results from right atrial contraction into a noncompliant right ventricle. Inspiration increases the intensity of both extra heart sounds.

The holosystolic, high-pitched, blowing murmur of tricuspid insufficiency often accompanies severe right ventricular dilation and failure. The murmur is best heard at the lower left sternal border. But in cases of severe right ventricular enlargement, the murmur may be displaced as far laterally as the left midclavicular line. The murmur intensifies with inspiration and decreases with expiration.

Signs of pulmonary hypertension include a closely split S 2 with a loud pulmonic component. The Graham Steell murmur of pulmonary hypertensive pulmonic regurgitation is a high-pitched, blowing diastolic murmur beginning with a loud P2 and continuing through most of diastole.


Hepatomegaly is common, usually presenting as a firm, hard liver that may be pulsatile. 

Elevated hydrostatic pressure within the hepatic veins and the peritoneal venous drainage system causes cardiac ascites. Protein-losing enteropathy with subsequent reduction of plasma oncotic pressure also may exacerbate ascites.

Splenomegaly may be found.

Fewer than 10% of patients exhibit jaundice.

Hepatic encephalopathy is rare.


Anorexia, weight loss, and malnutrition (ie, cardiac cachexia) indicate advanced underlying heart disease.



Diagnostic Considerations

Important considerations include the following:

  • Diagnose a correctable underlying cause of cardiac cirrhosis . For example, patients with alcoholism and cardiac disease who present with ascites may be misdiagnosed by attributing liver derangements to alcoholic cirrhosis.

  • Search for concomitant hepatobiliary disease in patients with either significantly or persistently elevated hepatic transaminases, alkaline phosphatase, or total bilirubin levels. For example, collecting a detailed social history may lead to the diagnosis of acute hepatitis B infection and prevent progression to end-stage liver failure.

  • Do not perform unnecessary liver biopsies.

  • Transjugular intrahepatic portosystemic shunt (TIPSS) is contraindicated in cardiac cirrhosis. It may precipitate acute right heart failure from an acute increase in pulmonary arterial pressure.

  • Adjust hepatically cleared medications.

Other conditions to consider in patients with cardiac cirrhosis and congestive hepatopathy include the following:

  • Biventricular congestive heart failure

  • Rright ventricular congestive heart failure

  • Hepatic veno-occlusive disease

  • Ischemic hepatitis

Differential Diagnoses



Laboratory Studies

Liver function tests

Evaluate severity of hepatic failure with liver function tests (LFTs), including hepatic transaminases, alkaline phosphatase, total bilirubin, and albumin.

The most common liver enzyme abnormality is an elevation of serum bilirubin. Patients with cardiac cirrhosis may exhibit modest elevations in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, and total bilirubin, as well as mild decreases in albumin.

Abnormal values are more common in patients with mean right atrial pressures in excess of 10 mm Hg and cardiac indices less than 1.5 L/min/m2.

Abnormalities typically remain clinically silent and resolve with compensation of heart failure.

Extreme elevations of AST and ALT should alert the clinician to other causes of liver failure, including ischemic, toxic, and viral hepatitis.

Prothrombin time

A study from the 1960s showed prothrombin time (PT) to be abnormal in as many as 80% of patients with acute or chronic right-sided heart failure.

Other laboratory studies

Evaluate serial cardiac enzymes, CBC count, urinalysis, and routine serum electrolytes in a patient with cardiac cirrhosis in the setting of new-onset heart failure.

Search for evidence of reversible causes of CHF. For example, obtain levels of serum iron, total iron-binding capacity, and ferritin in an evaluation for hemochromatosis when cardiac cirrhosis presents with significant or persistent LFT abnormalities. Thyroid-stimulating hormone (TSH) levels are indicated in patients with unexplained cardiac cirrhosis and atrial fibrillation.

In one study, investigators measured levels of inflammatory markers in cirrhotic patients with versus without ascites. They found that the plasma levels of the inflammatory cytokines interleukin (IL)-2, IL-4, IL-6, IL-8, interferon gamma (IFNγ), and epidermal growth factor (EGF) were significantly greater in the serum of cirrhotic patients with ascites, compared with the serum of cirrhotic patients without ascites (all P < 0.05). In addition, they found that serum procalcitonin levels were higher in cirrhotic patients with ascites, compared with cirrhotic patients without ascites.[8]

Chest Radiography

Radiographic images may show cardiomegaly, pulmonary venous hypertension, interstitial or pulmonary edema, or pleural effusion. Pleural effusions typically are larger on the right.


Transthoracic echocardiogram with Doppler

An echocardiogram may diagnose the underlying cause of cardiac cirrhosis. Evaluation of biventricular size, mass, function, wall motion, and valves are indicated.

Because restrictive cardiomyopathy and pericardial constriction can lead to cardiac cirrhosis, specific attention should be paid to diastolic function parameters such as mitral inflow, pulmonary vein flow, mitral annular flow, and their responses to respiration.

Lack of inferior vena cava (IVC) respiratory variation (normally greater than or equal to 50% narrowing during inspiration) or IVC diameter greater than or equal to 2.3 cm suggest right-sided cardiac disease with increased right atrial filling pressures.

Subcostal Doppler view of hepatic veins demonstrating systolic flow reversal is highly specific for clinically significant tricuspid regurgitation.

Radionuclide imaging

Radionuclide imaging with thallium or technetium is a noninvasive means to identify reversible cardiac ischemia in patients with cardiac cirrhosis in the setting of new or decompensated heart failure. Technetium-labeled agents and positron-emission tomography (PET) identify dilated cardiomyopathy and determine myocardial function.

Abdominal Doppler Ultrasonography

Consider abdominal Doppler US in the setting of ascites, right upper quadrant abdominal pain, jaundice, and/or abnormal serum LFTs that are refractory to effective treatment of underlying heart failure. The test is performed to search for an alternative diagnosis, such as Budd-Chiari syndrome.

Computed Tomography Scanning and Magnetic Resonance Imaging

CT scan and MRI help to diagnose restrictive and constrictive pericardial disease. These studies also may identify enlarged chamber size, ventricular hypertrophy, diffuse cardiomyopathy, valvular disease, and other structural abnormalities such as arrhythmogenic dysplasia of the right ventricle. Both can measure ejection fraction and effectively rule out cardiac cirrhosis. Body imaging may reveal evidence of cardiac cirrhosis, including hepatomegaly, hepatic congestion, IVC enlargement, and splenomegaly (see following images).

Cardiac cirrhosis and congestive hepatopathy. Cong Cardiac cirrhosis and congestive hepatopathy. Congestive hepatopathy with large renal vein.
Cardiac cirrhosis and congestive hepatopathy. Cong Cardiac cirrhosis and congestive hepatopathy. Congestive hepatopathy with large inferior vena cava.


Evidence of prior myocardial infarction, ventricular hypertrophy, and right atrial enlargement is common.

Right ventricular hypertrophy, right axis deviation, and right bundle-branch block may suggest chronic right ventricular pressure overload.


Diagnostic paracentesis may distinguish between cardiac and other etiologies of ascites. The information is useful especially in patients with chronic alcoholism and uncharacterized cardiac disease. Evaluate fluid for cell count and differential, albumin, total protein, and cytology.

Typically, cardiac ascites will reveal a high serum-ascites albumin gradient (SAAG) greater than 1.1 g/dL and a high ascitic fluid total protein greater than 2.5 g/dL. Patients with cirrhotic ascites also have a high SAAG value, but ascitic fluid total protein will be greater than 2.5 g/dL only 10% of the time.[9] See the Ascites Albumin Gradient calculator.

Employ therapeutic paracentesis for ascites refractory to diuretic treatment. Because hepatic albumin synthetic function usually is preserved in cardiac cirrhosis, parenteral albumin supplementation after paracentesis is not indicated.

Cardiac Catheterization and Coronary Angiography

The procedure may be indicated in patients with cardiac cirrhosis and heart failure in the context of known or suspected coronary artery disease. The study is employed primarily to evaluate coronary arterial anatomy and the need for revascularization.

Perform right heart catheterization to diagnose pulmonary hypertension in the setting of suggestive physical examination or echocardiographic findings.

In less than 1% of patients with chronic liver failure, pulmonary hypertension occurs in the absence of underlying pulmonary or cardiac disease. This entity, known as portopulmonary hypertension, may progress to right ventricular failure and present a diagnostic challenge to determine whether liver failure or heart disease is the primary lesion.


Needle liver biopsy

The procedure is not indicated routinely. Needle biopsy is indicated in heart transplant candidates with ascites to rule out cirrhosis.

Endomyocardial biopsy

The procedure may be indicated in patients with cardiac cirrhosis with deteriorating clinical condition and a strong clinical suspicion for myocarditis. It also may be indicated in the presence of a systemic disease with possible cardiac involvement, such as hemochromatosis or sarcoid.

Histologic Findings

Cardiac cirrhosis is associated with characteristic histologic changes. The presence of centrilobular parenchymal atrophy, sinusoidal and terminal hepatic venular distention, and perisinusoidal collagen deposition establishes chronic passive hepatic congestion (CPC).

In more severe cases, centrilobular fibrosis develops and eventually may include diffuse fibrous septa[10] and regenerative nodules characteristic of true cirrhosis.

Histologic findings are bland, with an absence of inflammatory cells.

Exposure of the liver to venous hypertension alone has not been demonstrated to cause centrilobular necrosis (CLN); in practice, however, histologic features of both CPC and CLN frequently occur together. CPC and CLN form a morphological continuum reflecting degrees of preexisting hepatic congestion and acute liver hypoperfusion. The synergistic combination of CPC and CLN is known as centrilobular hemorrhagic necrosis, referred to more commonly as nutmeg liver.[11]

The liver's mottled gross appearance results from the contrast of red-brown centrilobular regions suffused with blood against viable, if somewhat fatty, periportal tissue.

One group of investigators has developed a grading system for congestive hepatic fibrosis, as a histologic assessment of the clinical severity of hepatic passive congestion. The investigators found that the presence of portal fibrosis correlated with more severe impairment of right heart function, and they concluded that it is suggestive of more advanced hepatic passive congestion.[12]



Medical Care

No prospective studies have been performed to evaluate the medical treatment of cardiac cirrhosis. Because no data suggest that the presence of cardiac cirrhosis worsens mortality or morbidity rates, direct treatment at the underlying source of elevated right-sided heart pressure and hepatic venous congestion.

Note the following:

  • Initiate treatment in an inpatient setting, both to rule out ischemic heart disease and to administer IV diuretics.

  • In most cases, diuresis is the cornerstone of initial medical therapy for symptomatic relief.

  • Once the patient is euvolemic, beta-blockers and ace inhibitors should be added if the underlying cause is left ventricular dysfunction.

  • Spironolactone should be considered, especially if there is New York Heart Association class III or IV heart failure.

Consult with specialists in cardiology, gastroenterology, and diet and/or nutrition.

Surgical Care

Definitive treatment of cardiac cirrhosis sometimes requires surgical intervention, particularly when the underlying structural or anatomic lesion remains symptomatic despite maximal medical therapy.

Examples of surgical intervention include the following:

  • Coronary artery bypass surgery or percutaneous transluminal coronary angioplasty for ischemic cardiomyopathy

  • Tricuspid valve repair or replacement for tricuspid regurgitation or tricuspid stenosis

  • Pericardiectomy (cardiac decortication) for constrictive pericarditis

  • Peritoneovenous shunt not indicated to treat cardiac ascites

  • Transjugular intrahepatic portosystemic shunt (TIPSS): This is generally contraindicated because of the risk of acute right-sided decompensation from increased venous return. One recent case report illustrated the use of TIPSS procedure in a patient with cardiac cirrhosis after heart transplant that resulted in a successful outcome.[13]

  • Cardiac transplantation can be considered for end-stage cardiomyopathy. The presence of cardiac cirrhosis with significant liver fibrosis is considered a contraindication to transplantation. Although standard transplant criteria applies, several caveats should be considered. First, right-heart failure can be accompanied by significant pulmonary hypertension, which may necessitate combined heart-lung transplant. Second, synthetic liver function may be affected, leading to bleeding complications associated with transplantation. However, a study examining the reversibility of cardiac cirrhosis in patients undergoing heart transplant showed that synthetic function significantly improved within 3 months after transplant.[14]


Sodium restriction is a fundamental component of long-term management. The sodium intake goal is less than 2 g/d.


A sensible exercise program is appropriate for most patients with cardiac cirrhosis after medical control of their underlying heart failure.

Long-Term Monitoring

Instruct patients to maintain a diary of their daily weights. Specific instructions may be issued to increase the patient's oral diuretic dose, as well as to return for immediate medical evaluation when certain weight increases are exceeded (eg, 2 lb/d or 5 lb/wk).

Schedule periodic follow-up. Monitor symptoms, preferably using well-defined activities (eg, walking 100 ft on ground level, climbing 1-2 flights of stairs).

Follow serum levels of potassium, blood urea nitrogen (BUN), creatinine, aspartate aminotransaminase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]), alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase [SGPT]), alkaline phosphatase (ALP), and total bilirubin. All should normalize with attainment of heart failure compensation. Failure of levels to resolve despite heart failure resolution should prompt evaluation of noncardiac sources of liver disease.



Medication Summary

With few exceptions (eg, acute right ventricular myocardial infarction), diuresis is the cornerstone of initial management of cardiac cirrhosis. As cardiac cirrhosis is a direct complication of elevated central venous pressures, effective diuresis should improve hepatic derangements. Lack of improvement should prompt a search for primary hepatic disease.

Beyond diuretics, medical therapy should be directed at treating underlying heart failure and correcting the source of elevated right-sided heart pressures.


Class Summary

Initial treatment of cardiac cirrhosis usually requires a loop diuretic (eg, furosemide). Spironolactone may provide additional diuresis through its aldosterone antagonism effects.

Furosemide (Lasix)

Increases excretion of water by interfering with chloride-binding cotransport system, which in turn inhibits sodium and chloride reabsorption in ascending loop of Henle and distal renal tubule.

Initial administration should be IV to avoid poor bowel absorption through edematous bowel mucosa. Start dosing low and increase to achieve desired diuresis and clinical effect. Useful clinical target is return to patient's baseline weight.

Rising serum BUN and creatinine levels are indicators of prerenal azotemia and suggest maximal diuresis has been achieved. Once determined, administer effective dose qd or bid.

Spironolactone (Aldactone)

For management of edema resulting from excessive aldosterone levels secondary to hepatic cirrhosis or CHF. Competes with aldosterone for receptor sites in distal renal tubules, increasing water excretion while retaining potassium and hydrogen ions.



Further Inpatient Care

With few exceptions, patients presenting with cardiac cirrhosis and acute heart failure symptoms require hospital admission. This is particularly true in the initial presentation of heart failure.

Admission also is indicated when chronic symptoms become refractory to outpatient therapy and large doses of oral diuretics do not provide adequate diuresis.

Consider initial admission to a telemetry unit for continuous ECG monitoring.


Consider initial transfer to a telemetry ward for continuous ECG monitoring with new presentations of cardiac cirrhosis.

Transfer to a tertiary care facility may be warranted for surgical treatment of the following:

  • Atherosclerotic coronary artery disease - Either with percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass surgery

  • Severe valvular disease

  • Constrictive pericarditis


The patient may prevent hospitalization for heart failure by enrolling in a heart failure clinic or agreeing to frequent brief physician visits for any of the following:

  • Reinforcing recognition of early heart failure symptoms

  • Close following of daily weight log

  • Encouraging adherence to a low-sodium diet

  • Reviewing medical compliance

  • Drug interactions


Possible complications include acute renal failure secondary to overdiuresis.


The independent effect of cardiac cirrhosis on morbidity or mortality rate is unknown. Prognosis is based on the patient's underlying heart failure condition.

Patient Education

Additional patient information may be found at Heart Failure Online and Health Central.

For patient education resources, see the Heart Health Center, as well as Congestive Heart Failure.


Questions & Answers


What is cardiac cirrhosis (congestive hepatopathy)?

What is the pathophysiology of cardiac cirrhosis (congestive hepatopathy)?

What causes cardiac cirrhosis (congestive hepatopathy)?

What is the role of the Fontan procedure in the etiology of cardiac cirrhosis (congestive hepatopathy)?

What is the US prevalence of cardiac cirrhosis (congestive hepatopathy)?

Which patient groups have the highest prevalence of cardiac cirrhosis (congestive hepatopathy)?

What is the prognosis of cardiac cirrhosis (congestive hepatopathy)?

What is the mortality and morbidity associated with cardiac cirrhosis (congestive hepatopathy)?


Which clinical history findings are characteristic of cardiac cirrhosis (congestive hepatopathy)?

What are the signs and symptoms of right-sided heart failure in cardiac cirrhosis (congestive hepatopathy)?

What are the signs and symptoms of biventricular heart failure in cardiac cirrhosis (congestive hepatopathy)?

Which physical findings are characteristic of cardiac cirrhosis (congestive hepatopathy)?

Which physical findings are characteristic of edema in cardiac cirrhosis (congestive hepatopathy)?

Which jugular venous pressure findings are characteristic of cardiac cirrhosis (congestive hepatopathy)?

Which lung exam findings are characteristic of cardiac cirrhosis (congestive hepatopathy)?

Which cardiac exam findings are characteristic of cardiac cirrhosis (congestive hepatopathy)?

Which hepatic findings are characteristic of cardiac cirrhosis (congestive hepatopathy)?

What are the signs of advanced underlying heart disease in cardiac cirrhosis (congestive hepatopathy)?


What should be considered when cardiac cirrhosis (congestive hepatopathy) is suspected?

Which conditions are included in the differential diagnosis of cardiac cirrhosis (congestive hepatopathy)?

What are the differential diagnoses for Cardiac Cirrhosis and Congestive Hepatopathy?


What is the role of liver function tests in the workup of cardiac cirrhosis (congestive hepatopathy)?

What is the role of prothrombin time (PT) tests in the workup of cardiac cirrhosis (congestive hepatopathy)?

What is the role of lab tests in the workup of cardiac cirrhosis (congestive hepatopathy)?

What is the role of chest radiography in the workup of cardiac cirrhosis (congestive hepatopathy)?

What is the role of echocardiography in the workup of cardiac cirrhosis (congestive hepatopathy)?

What is the role of radionuclide imaging in the workup of cardiac cirrhosis (congestive hepatopathy)?

What is the role of ultrasonography in the workup of cardiac cirrhosis (congestive hepatopathy)?

What is the role of CT scanning and MRI in the workup of cardiac cirrhosis (congestive hepatopathy)?

What is the role of electrocardiography in the workup of cardiac cirrhosis (congestive hepatopathy)?

What is the role of paracentesis in the workup of cardiac cirrhosis (congestive hepatopathy)?

What is the role of cardiac catheterization in the workup of cardiac cirrhosis (congestive hepatopathy)?

What is the role of liver needle biopsy in the workup of cardiac cirrhosis (congestive hepatopathy)?

What is the role of endomyocardial biopsy in the workup of cardiac cirrhosis (congestive hepatopathy)?

Which histologic findings are characteristic of cardiac cirrhosis (congestive hepatopathy)?


How is cardiac cirrhosis (congestive hepatopathy) treated?

What is the role of surgery in the treatment of cardiac cirrhosis (congestive hepatopathy)?

Which dietary modifications are used in the treatment of cardiac cirrhosis (congestive hepatopathy)?

Which activity modifications are used in the treatment of cardiac cirrhosis (congestive hepatopathy)?

What is included in the long-term monitoring for cardiac cirrhosis (congestive hepatopathy)?


What is the role of medications in the treatment of cardiac cirrhosis (congestive hepatopathy)?

Which medications in the drug class Diuretics are used in the treatment of Cardiac Cirrhosis and Congestive Hepatopathy?


When is inpatient care indicated for the treatment of cardiac cirrhosis (congestive hepatopathy)?

When is patient transfer indicated for the treatment of cardiac cirrhosis (congestive hepatopathy)?

How is cardiac cirrhosis (congestive hepatopathy) prevented?

What are the possible complications of cardiac cirrhosis (congestive hepatopathy)?

Which factors affect the prognosis of cardiac cirrhosis (congestive hepatopathy)?

Where can patient education resources for cardiac cirrhosis (congestive hepatopathy) be found?